The cannabinoid CB1 receptor antagonist SR141716A (Rimonabant) enhances the metabolic benefits of long-term treatment with oleoylethanolamide in Zucker rats
Antonia Serrano, Ignacio del Arco, Francisco Javier Pavón, Manuel Macías, Vidal Perez-Valero, Fernando Rodríguez de FonsecaVolume:
54
Year:
2008
Language:
english
DOI:
10.1016/j.neuropharm.2007.03.007
File:
PDF, 354 KB
english, 2008